NAD+
InjectionLongevity
TabletLongevityIn stock
Rapamycin tablet
A rapamycin tablet for longevity programs that want the most-discussed mTOR molecule as a premium, consult-led offer, with the intake, provider-review, and refill infrastructure a higher-touch protocol needs.
Cadence
Often weekly
Pathway
mTOR modulation
Format
Oral tablet, intermittent dosing common
Label status
FDA-approved drug, off-label for longevity
Rx required
Yes, licensed provider review
Monitoring
Lab and follow-up oriented
About the protocol
The flagship mTOR molecule for serious longevity programs
Rapamycin, also called sirolimus, is an FDA-approved drug used in transplant medicine that inhibits the mTOR pathway. In longevity practice it is used off-label, often on an intermittent weekly schedule, based on strong animal lifespan data and a still-immature human longevity evidence base. It is the molecule longevity patients ask about most after NAD and peptides, which makes it a credible premium anchor, as long as the program treats it as a supervised protocol rather than a casual add.
- Inhibits the mTOR pathway, the cellular-maintenance target at the center of longevity interest
- Used off-label and often intermittently, which calls for clear provider direction on schedule
- Mechanistically compelling, with human longevity outcomes still unproven, so claims must stay measured
- Best run with screening, monitoring, and follow-up rather than as a simple recurring refill
Mechanism
An mTOR inhibitor, the most-studied pathway in the cellular-maintenance layer of a longevity stack.
Delivery
An oral tablet, commonly dosed on an intermittent weekly schedule in longevity use.
Evidence
Promising mechanistically and in animal models, with human longevity data still immature.
Oversight
Provider review, lab monitoring, and follow-up matter more here than for lighter SKUs.
Program design
A premium, supervised anchor, not a casual add
Rapamycin belongs in programs that already run consult-led longevity memberships. It carries the strongest brand interest of the cellular-maintenance layer, but it asks for real screening, monitoring, and conservative messaging in return.
High patient interest
It is one of the most-requested longevity molecules, which makes it a strong premium-tier offer.
Monitoring-led workflow
Intermittent dosing, labs, and follow-up are central, so it fits clinics that can support oversight.
Evidence-honest claims
Human longevity outcomes are unproven, so the page should describe mechanism and interest, not promises.
Rapamycin is FDA-approved for other indications and is used off-label for longevity. Screening for infections, interactions, and immune considerations belongs in provider review.
Launch flow
A simple launch flow for rapamycin
The cleanest setup keeps the public page focused on the supervised nature of the protocol and lets the provider own dose, schedule, and monitoring.
- 1Step 1Intake and eligibilityCollect goals, full medication list, infection and immune history, and contraindications, then route to a licensed provider.
- 2Step 2Provider review and scheduleThe provider sets an appropriate intermittent schedule, explains the off-label and evidence context, and orders any baseline labs.
- 3Step 3Monitoring and continuationUse follow-ups and labs to assess tolerability and decide whether to continue, adjust the schedule, or pause.
Intermittent dosing and monitoring are clinician decisions. The public page should set the expectation that this is a supervised protocol, not a self-managed refill.
Format comparison
Interactive operator view
Compare how rapamycin usually behaves operationally versus metformin, the other common off-label cellular-maintenance option. Planning dimensions, not clinical outcome comparisons.
Format comparison by operator dimension
Hover to compare rapamycin versus metformin.
RapamycinMetformin
Strongest current edge
Patient interest
Rapamycin scores 92/100 on this dimension.
Clearest difference
Premium positioning
This is where the two NAD+ formats separate the most in program design terms.
Needs the most support
Human longevity data
This is the weakest current score in the comparison, so it is the area most likely to need extra workflow design.
Illustrative operator-planning view based on demand, mechanism interest, and oversight needs. Not a statement of safety or efficacy for any individual patient.
The Turbopills stack for this program
Everything you need to run a rapamycin program
Use your own brand, your own providers, and your own price. The platform ships the intake, provider-review workflow, monitoring touchpoints, billing, and refill logic for a supervised premium offer.
Product website & ad landing pages
Turbopills AI Studio — ad images & videos
BetaProvider review & e-Rx
Pharmacy order routing
Refills & auto-ship
Experiments & A/B tests
BetaReady to launch
Bring a rapamycin offer online as a supervised premium tier.
The platform ships the intake, provider-review logic, monitoring reminders, billing, and refill cadence so your team can launch a credible longevity flagship on one backend instead of stitching vendors together.
Marketing and educational content only. Clinical details on this page are summarized from publicly available sources to help operators scope a program — they are not medical advice, dosing instructions, or a recommendation for any individual patient. Real patient care requires a licensed provider and a compliant pharmacy partner; Turbopills provides the software that helps brands run the program around them.
Related
